Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Vaage S, Tammela TL, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJ; Casodex Early Prostate Cancer Trialist Group, Medical College of Wisconsin, Milwaukee, WI - J Urol 2002;168:429-43

By Trump D.L.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 5, 2003-09 ,pp. : 408-409

Elsevier

Access to resources Recommend Favorite

The UCSF advanced prostate cancer program

By Small E.J.   Harris K.A.   Frohlich M.W.   Bok R.  

Urologic Oncology: Seminars and Original Investigations, Vol. 6, Iss. 5, 2001-09 ,pp. : 197-201

Elsevier

Access to resources Recommend Favorite

The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer

By See William   Tyrrell Chris  

Journal of Cancer Research and Clinical Oncology, Vol. 132, Iss. 1, 2006-08 ,pp. : 7-16

Springer Publishing Company

Access to resources Recommend Favorite

The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer

By See William   Tyrrell Chris  

Journal of Cancer Research and Clinical Oncology, Vol. 132, Iss. 13, 2006-08 ,pp. : 7-16

Springer Publishing Company

Access to resources Recommend Favorite

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models

By            

International Journal of Oncology, Vol. 41, Iss. 2, 2012-01 ,pp. : 425-432

Spandidos Publications

Access to resources Recommend Favorite